MedPath

Effect of Vitex Plant on Female Sexual Functio

Phase 3
Conditions
Sexual dysfunction.
Hypoactive sexual desire disorder
F52.0
Registration Number
IRCT20100503003860N36
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
102
Inclusion Criteria

Fertile women 15-44 years who referred for Pap smear
Healthy in gynecological and physical examinations
Seeking treatment for the improvement and enhancement of sexual function

Exclusion Criteria

single
Pregnant and lactating
Illiterate / cannot read and write
Having a specific illness (thyroid problems, diabetes, psychiatric disorders, hyper-prolactonemia, liver problems, etc.)
Stressful event in the last 6 months (death or disease of immediate family member, a major change in lifestyle) of any of the couples
Mental problems (illness under the supervision or treatment of a physician) in each of the couples according to the woman's statement
Treated for any sexual problems in each of the couples according to the woman's statement
Alcohol or drug addiction in each of the couples according to the woman's statement
Women whose husbands are unable to have normal sex (e.g., erectile dysfunction or premature ejaculation)
Any illness in women, including abnormal bleeding, cervicitis and vaginitis without premenstrual tension and premenstrual syndrome.
Taking vitamin supplements or hormonal pills like contraceptives

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Sexual function. Timepoint: Before the intervention, 4,812 and 16 weeks after the intervention. Method of measurement: Female Sexual Function Index questionnaire.
Secondary Outcome Measures
NameTimeMethod
Sexual desire score. Timepoint: Before the intervention, 4, 8,12 and 16 weeks after the intervention. Method of measurement: Female Sexual Function Index questionnaire.;Sexual Arousal Score. Timepoint: Before the intervention, 4, 8,12 and 16 weeks after the intervention. Method of measurement: Female Sexual Function Index questionnaire.;Orgasm Score. Timepoint: Before the intervention, 4, 8,12 and 16 weeks after the intervention. Method of measurement: Female Sexual Function Index questionnaire.;Coitus of Pain Score. Timepoint: Before the intervention, 4, 8,12 and 16 weeks after the intervention. Method of measurement: Female Sexual Function Index questionnaire.;Sexual Satisfaction Score. Timepoint: Before the intervention, 4, 8,12 and 16 weeks after the intervention. Method of measurement: Female Sexual Function Index questionnaire.
© Copyright 2025. All Rights Reserved by MedPath